Med Lett Drugs Ther. 2011 May 30;53(1365):42-3.
The FDA has approved a topical 8% patch formulation of capsaicin (Qutenza-NeurogesX), available only by prescription, for local treatment of postherpetic neuralgia. Postherpetic neuralgia occurs after herpes zoster in about one third of patients ≥60 years old and can persist for months or even years.
美国食品药品监督管理局(FDA)已批准一种仅可凭处方购买的8%辣椒素局部贴剂(Qutenza - NeurogesX),用于带状疱疹后神经痛的局部治疗。带状疱疹后神经痛在≥60岁的患者中约三分之一会在带状疱疹后发生,且可持续数月甚至数年。